跳至主要内容
临床试验/CTRI/2023/01/048782
CTRI/2023/01/048782招募中未知

Efficacy and safety of oral hydroxyurea on Bcl11 and Xmn1 expression levels in transfusion-dependent β-thalassaemia: a randomized double-blind controlled clinical trial.

Multidisciplinary Research Unit MR0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Patients aged 6 years and above.
  • Patients with confirmed genotypes of homozygous/ compound heterozygous β-thalassaemia major or HbE β-thalassaemia.
  • Patients who required more than eight blood transfusions during the preceding 12 months.

排除标准

  • Sickle β-thalassaemia
  • Coexisting chronic liver disease
  • Coexisting chronic kidney disease
  • Coexisting viral hepatitis
  • Patients with contraindications for hydroxyurea (e.g., hypersensitivity, bone marrow depression, pregnancy and lactation)
  • Patients who are expecting to get pregnant during the next 12 months
  • Patients who have undergone bone marrow transplantation
  • Patients on immunosuppressant therapy
  • Baseline serum ferritin >5000 ng/mL
  • Baseline white cell count <4000/μL
  • Baseline platelet count <1 50 000/μL
  • Patients who were started on regular transfusions for a predetermined limited period

研究者

发起方
Multidisciplinary Research Unit MR

相似试验

Efficacy and safety of oral hydroxyurea on gene... | 临床试验